Nadunolimab

立即咨询

Nadunolimab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议

产品介绍

Nadunolimab 是一种靶向IL1RAP的人 IgG1 单克隆抗体。Nadunolimab 阻断 IL-1α 和 IL-1β 信号并触发抗体依赖性细胞毒性。Nadunolimab 可用于癌症的研究。

生物活性

Nadunolimab is a human monoclonalIgG1antibody targetingIL1RAP. Nadunolimab blocks IL-1α and IL-1β signaling and triggering antibody-dependent cellular cytotoxicity. Nadunolimab can be used in research ofcancer^[1].

IC₅₀& Target

IL-1α

IL-1β

体外研究
(In Vitro)

Nadunolimab (20 μg/mL; 30 min and 1 h; A549 cells and BxPC3 cells) reduces IL-1α-induced release of pro-infamma tory cytokines and chemokines, including IL-1β, IL-6 TNF-α and MIP-1α, and CXCL1^[1].

体内研究
(In Vivo)

Nadunolimab (10 mg/kg; i.p.; twice on day 1 and thereafter twice weekly; nude BALB/c mice with LU2503 or MC38 tumors) improves the anti-tumor efficacy of chemotherapy and blocks both murine IL-1α and IL-1β signaling^[1].

Animal Model:	Nude BALB/c mice with LU2503 or MC38 tumors^[1]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; twice on day 1 and thereafter twice weekly
Result:	Reduced tumor volume in combination withCisplatin(HY-17394) andGemcitabine(HY-17026). Blocked both murine IL-1α and IL-1β signaling.

Clinical Trial

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.